Market Cap 131.92M
Revenue (ttm) 103.46M
Net Income (ttm) -227.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 6.91
Profit Margin -219.61%
Debt to Equity Ratio -0.10
Volume 196,300
Avg Vol 445,104
Day's Range N/A - N/A
Shares Out 31.86M
Stochastic %K 40%
Beta 1.43
Analysts Sell
Price Target $12.33

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 674 4400
Fax: 781 674 4200
Address:
3 Forbes Road, Lexington, United States
neversurrender2024
neversurrender2024 Oct. 27 at 8:41 PM
$AGEN garos atm alive and well...years away from any approval folks....
0 · Reply
BillyBobBleach
BillyBobBleach Oct. 27 at 5:27 PM
$AGEN Big partnership has got to be finalizing. Competition is at the doorstep and no Zydus deal closure.
2 · Reply
joechuck71
joechuck71 Oct. 27 at 5:22 PM
$AGEN Received additional questions of interest! wow
0 · Reply
joechuck71
joechuck71 Oct. 27 at 5:05 PM
$AGEN Believe it or not just got a reply from my god daughter that they will be looking this all over and will get back to me. Interesting!
0 · Reply
joechuck71
joechuck71 Oct. 27 at 3:08 PM
$AGEN Just sent My God Daughter who is a producer for documentary's films for TV , Netflix and prime the link to the short video from the stockholders meeting Augst 27 on YouTube. I told her as much as I could and how it needs world exposer to save lives. I can't guaranty anything and nothing happens fast in the film world, but I tried. I also emailed The Bill Gates Foundation sent them the video as well. It's time we all try to get the word out already you can't make everything in life about money doing the right thing and helping people in need will make you feel like a million bucks let's go!
2 · Reply
BiotechBagholder
BiotechBagholder Oct. 27 at 1:01 PM
$AGEN Interesting ESMO recap by Leerink/Truist here. There's a discussion on MSS CRC starting at about the 20:00 mark. They also discuss the STELLAR-303 data and market opportunity for zanzalintinib a bit later. Summit is initiating a Phase 3 trial of ivonescimab (PD-1xanti-VEGF bispecific) in 1L MSS CRC. Incyte is initiating a registrational program for INCA33890, (TGFβR2×PD-1 bispecific) in 3L MSS CRC. https://www.bloomberg.com/professional/insights/webinar/post-esmo-wrap-with-leerink-partners-bi-replay/.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 27 at 3:33 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AGEN Current Share Price: $4.14 Contracts: $AGEN January 15, 2027 $5 Calls Scale in: $1.52- $1.86 Scale out: $2.36-$3.04 Can Easily Capture: 60% ROI Blended DTE: 446 Days | Join Elites here: https://liquidtheta.com
0 · Reply
UltimoDaBaggie
UltimoDaBaggie Oct. 26 at 7:12 PM
$AGEN Agree that adverse events with zanzalintinib is significant https://x.com/altaioncology/status/1982512948145684790?s=46
0 · Reply
Biotechguy21
Biotechguy21 Oct. 26 at 5:15 PM
$AGEN some never learn. 😂😂😂🤡🤡🤡
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 26 at 5:35 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AGEN Current Share Price: $4.14 Contracts: $AGEN January 15, 2027 $5 Calls Scale in: $1.52- $1.86 Scale out: $2.36-$3.04 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Latest News on AGEN
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

Oct 21, 2025, 8:44 PM EDT - 6 days ago

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript


Agenus Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:30 PM EDT - 4 months ago

Agenus Announces Virtual Annual Shareholders Meeting


Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 4, 2025, 2:38 PM EDT - 5 months ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang


Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

May 23, 2025, 3:09 PM EDT - 5 months ago

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide


Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 2:46 PM EDT - 6 months ago

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript


Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 10:39 AM EDT - 8 months ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript


Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:41 AM EST - 1 year ago

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript


neversurrender2024
neversurrender2024 Oct. 27 at 8:41 PM
$AGEN garos atm alive and well...years away from any approval folks....
0 · Reply
BillyBobBleach
BillyBobBleach Oct. 27 at 5:27 PM
$AGEN Big partnership has got to be finalizing. Competition is at the doorstep and no Zydus deal closure.
2 · Reply
joechuck71
joechuck71 Oct. 27 at 5:22 PM
$AGEN Received additional questions of interest! wow
0 · Reply
joechuck71
joechuck71 Oct. 27 at 5:05 PM
$AGEN Believe it or not just got a reply from my god daughter that they will be looking this all over and will get back to me. Interesting!
0 · Reply
joechuck71
joechuck71 Oct. 27 at 3:08 PM
$AGEN Just sent My God Daughter who is a producer for documentary's films for TV , Netflix and prime the link to the short video from the stockholders meeting Augst 27 on YouTube. I told her as much as I could and how it needs world exposer to save lives. I can't guaranty anything and nothing happens fast in the film world, but I tried. I also emailed The Bill Gates Foundation sent them the video as well. It's time we all try to get the word out already you can't make everything in life about money doing the right thing and helping people in need will make you feel like a million bucks let's go!
2 · Reply
BiotechBagholder
BiotechBagholder Oct. 27 at 1:01 PM
$AGEN Interesting ESMO recap by Leerink/Truist here. There's a discussion on MSS CRC starting at about the 20:00 mark. They also discuss the STELLAR-303 data and market opportunity for zanzalintinib a bit later. Summit is initiating a Phase 3 trial of ivonescimab (PD-1xanti-VEGF bispecific) in 1L MSS CRC. Incyte is initiating a registrational program for INCA33890, (TGFβR2×PD-1 bispecific) in 3L MSS CRC. https://www.bloomberg.com/professional/insights/webinar/post-esmo-wrap-with-leerink-partners-bi-replay/.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 27 at 3:33 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AGEN Current Share Price: $4.14 Contracts: $AGEN January 15, 2027 $5 Calls Scale in: $1.52- $1.86 Scale out: $2.36-$3.04 Can Easily Capture: 60% ROI Blended DTE: 446 Days | Join Elites here: https://liquidtheta.com
0 · Reply
UltimoDaBaggie
UltimoDaBaggie Oct. 26 at 7:12 PM
$AGEN Agree that adverse events with zanzalintinib is significant https://x.com/altaioncology/status/1982512948145684790?s=46
0 · Reply
Biotechguy21
Biotechguy21 Oct. 26 at 5:15 PM
$AGEN some never learn. 😂😂😂🤡🤡🤡
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 26 at 5:35 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AGEN Current Share Price: $4.14 Contracts: $AGEN January 15, 2027 $5 Calls Scale in: $1.52- $1.86 Scale out: $2.36-$3.04 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
joechuck71
joechuck71 Oct. 25 at 6:21 PM
$AGEN News coming lowest short interest in many years 10/15/2025 1,943,316 not many shorts left
1 · Reply
chrisdacs
chrisdacs Oct. 25 at 1:37 AM
$AGEN this stupid is stock.
0 · Reply
Biotechguy21
Biotechguy21 Oct. 25 at 12:22 AM
$AGEN look who is back 👀 and this means look out below 😂😂
0 · Reply
Scooter0732
Scooter0732 Oct. 24 at 8:36 PM
$AGEN The push continues https://dcjournal.com/fda-must-keep-up-with-science-on-cancer/
5 · Reply
Overcrumb
Overcrumb Oct. 24 at 7:16 PM
$AGEN most stocks having a nice upside today. Agenus sinking again.
0 · Reply
2_logs_higher
2_logs_higher Oct. 24 at 5:40 PM
$AGEN & $INCY, $LLY INCY needs to buy needs to buy Agen LLY needs to buy INCY New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) https://finance.yahoo.com/news/lillys-baricitinib-delivered-near-complete-104500483.html?guccounter=1
1 · Reply
2_logs_higher
2_logs_higher Oct. 24 at 5:35 PM
$AGEN & $INCY INCY needs to buy Agenus! New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) https://finance.yahoo.com/news/lillys-baricitinib-delivered-near-complete-104500483.html?guccounter=1
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 24 at 3:13 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AGEN Current Share Price: $4.18 Contracts: $AGEN January 15, 2027 $5 Calls Scale in: $1.52- $1.86 Scale out: $2.36-$3.04 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
BakerBrother
BakerBrother Oct. 24 at 2:08 PM
$AGEN Clear sailing ahead.
0 · Reply
BakerBrother
BakerBrother Oct. 24 at 11:32 AM
$AGEN Three takeaways from Wednesday’s call: 1) We will get a neodjuvant trial sponsored by Agenus 2) Agenus has submitted the additional info requested by CFIUS, however, the 45 day clock from accepted has not begun. 3) We will see 2-year OS data for the MSS-CRC trial when data matures. The fact that responses are still ongoing is a +. What else did I miss?
3 · Reply
UltimoDaBaggie
UltimoDaBaggie Oct. 23 at 9:07 PM
$AGEN Just read the Lancet paper on zanzalintinib. Response is not as good as bot/bal but its a phase 3 with hundreds of pts so cannot really compare. However, toxicity seems significant which is a game changer for 3rd line treatment Also read the final NICHE results in Nature. Only abstract. I dont have access to full text. Results are subpar to bot/bal Finally, read the ESMO abstract on regorafenib/bot/bal combo => Very few responses but bot dose was only 25 mg. For comparison, in our phase 2 dose was 75/150 mg. But still significant toxicity due to TKIs at that dose. My conclusion: 1. Bot/bal is still the best IO combo - at least for colorectal. 2. Combinations with TKIs will not work well, primarily 2/2 DLTs
1 · Reply
joechuck71
joechuck71 Oct. 23 at 6:18 PM
$AGEN "Zynext Ventures is heading to hashtag#BIO-Europe in Vienna!" Nov 2 and 3
0 · Reply